3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
CNS
2
Conditions
Meningeal Carcinomatosis
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Interventions
Temozolomide
163
Radiosurgery
129
Radiotherapy
107
Bevacizumab
98
Magnetic Resonance Spectroscopy
75
Carboplatin
48
Surgical Procedures, Operative
35
pembrolizumab
34
Radiation
34
Etoposide
34
Nivolumab
33
Irinotecan
33
Cyclophosphamide
33
Erlotinib Hydrochloride
31
Carmustine
28
Trastuzumab
25
Lomustine
25
Cisplatin
25
Ipilimumab
24
Filgrastim
23
Mental Status and Dementia Tests
21
Magnetic Resonance Imaging
21
Aminolevulinic Acid
21
Vincristine
20
Surveys and Questionnaires
19
Capecitabine
19
Topotecan
18
Specimen Handling
18
Pemetrexed
18
Radiotherapy, Intensity-Modulated
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
AZD3759
×
CNS
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled
NCT02228369
2021-01-05
BLOOM
AstraZeneca
Phase 1
Completed
108 enrolled